Cortistatin Protocol: Complete Cycling & Dosing Guide

Cortistatin Protocol: Complete Cycling & Dosing Guide

Overview

Cortistatin is an endogenous neuropeptide structurally related to somatostatin with potent immunomodulatory and anti-inflammatory properties. Unlike somatostatin, cortistatin uniquely binds ghrelin receptors and MrgX2, creating a distinctive neuroendocrine and sleep-promoting profile. The compound binds all five somatostatin receptors (SSTR1-5) with high affinity while simultaneously activating growth hormone secretagogue receptors and mast cell-modulating pathways.

Important: Cortistatin remains an investigational compound with no approved clinical use. It is research-only material. Self-administration outside supervised clinical contexts carries unknown risks due to the absence of human pharmacokinetic and toxicology data. This guide is educational content, not medical advice.

Standard Protocol

Dose Range: 10–100 mcg/kg body weight, administered once daily via injection

Route: Subcutaneous or intravenous injection

Cycle Length: 4–12 weeks, depending on therapeutic objective

Rest Period: 2–4 weeks between cycles minimum

Typical Starting Dose: 20–30 mcg/kg for initial assessment of tolerance

Standard Maintenance: 50–70 mcg/kg once daily during active cycling

Maximum Recommended: 100 mcg/kg, reserved for intensive anti-inflammatory or immune-modulation protocols

For a 180-pound (82 kg) individual:

• Starting dose: 1.6–2.5 mg daily
• Standard maintenance: 4.1–5.7 mg daily
• Maximum dose: 8.2 mg daily

Goal-Specific Protocols

Anti-Inflammatory & Immune Modulation (Tier 2 Evidence)

Duration: 8–12 weeks

Dose Escalation:

• Weeks 1–2: 30 mcg/kg daily
• Weeks 3–6: 50 mcg/kg daily
• Weeks 7–12: 70–100 mcg/kg daily

Rationale: Cortistatin suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-12) while upregulating anti-inflammatory IL-10. Higher doses and extended duration target systemic immune dysregulation.

Expected Timeline:

• Days 3–7: Initial suppression of acute phase reactants
• Weeks 2–3: Measurable reduction in inflammatory markers
• Weeks 4–8: Peak anti-inflammatory effects
• Weeks 9–12: Sustained immune modulation

Recovery: 3-week minimum rest before re-cycling

Joint & Cartilage Protection (Tier 2 Evidence)

Duration: 10–12 weeks

Dose Escalation:

• Weeks 1–2: 25 mcg/kg daily
• Weeks 3–10: 60 mcg/kg daily
• Weeks 11–12: 70 mcg/kg daily

Rationale: Cortistatin protects cartilage and bone through anti-inflammatory mechanisms while inhibiting Th1-mediated autoimmune joint destruction. Sustained dosing prevents cartilage degradation.

Expected Timeline:

• Weeks 1–2: Establishment of systemic tolerance
• Weeks 3–5: Initial reduction in joint inflammation
• Weeks 6–10: Progressive cartilage-protective effects
• Weeks 11–12: Stabilization of joint structure

Recovery: 4-week minimum rest; consider bone health support compounds during recovery

Sleep Enhancement & Cognitive Recovery (Tier 2 Evidence)

Duration: 6–8 weeks

Dose Escalation:

• Weeks 1–2: 20 mcg/kg daily (evening administration)
• Weeks 3–6: 40 mcg/kg daily (evening administration)
• Weeks 7–8: 50–60 mcg/kg daily (evening administration)

Timing: Administer 30–60 minutes before intended sleep window for optimal slow-wave sleep promotion

Rationale: Cortistatin-14 selectively enhances EEG synchronization and deep slow-wave sleep. Evening dosing aligns with sleep promotion mechanisms. Ghrelin receptor activation supports appetite and metabolic alignment with sleep cycles.

Expected Timeline:

• Days 1–3: Possible initial sedation
• Days 4–10: Onset of slow-wave sleep enhancement
• Weeks 2–4: Peak sleep quality improvement and EEG delta wave elevation
• Weeks 5–8: Sustained cognitive recovery during sleep phases

Recovery: 2-week minimum rest; sleep quality typically normalizes within 3–5 days post-cycle

Gut Health & Inflammatory Bowel Support (Tier 2 Evidence)

Duration: 8–10 weeks

Dose Escalation:

• Weeks 1–2: 30 mcg/kg daily
• Weeks 3–8: 50–70 mcg/kg daily
• Weeks 9–10: 70 mcg/kg daily

Timing: Morning administration preferred for GI transit optimization

Rationale: Cortistatin ameliorates colitis severity and inhibits GI transit dysfunction. SSTR2/5 activation supports mucus layer integrity and barrier function.

Expected Timeline:

• Weeks 1–2: Initial stabilization of bowel symptoms
• Weeks 3–5: Reduction in inflammatory markers
• Weeks 6–8: Peak mucosal healing
• Weeks 9–10: Sustained barrier restoration

Recovery: 3-week minimum rest with continued GI support supplementation

How to Administer Step-by-Step

Reconstitution (if lyophilized)

1. Calculate total dose requirement for cycle (weight × mcg/kg × number of days)
2. Obtain sterile bacteriostatic saline or sterile water for injection
3. Using a sterile syringe and 25–27 gauge needle, withdraw calculated saline volume
4. Inject saline slowly into vial containing lyophilized cortistatin
5. Allow 30–60 seconds for dissolution without shaking
6. Gently roll vial between palms until completely dissolved (do not shake vigorously)
7. Allow 5 minutes for foam to settle
8. Solution should appear clear; if cloudy or discolored, discard and prepare fresh

Storage Post-Reconstitution

• Reconstituted solution: Refrigerate at 2–8°C, stable for 7–14 days depending on diluent
• Lyophilized powder: Store at room temperature (15–25°C) or refrigerated; keep desiccated
• Reconstituted for daily use: Prepare fresh solution every 3–5 days maximum
• Syringes: Use sterile 1 mL tuberculin or 3 mL syringe with 27–31 gauge needle

Injection Procedure

Subcutaneous Administration (preferred for home use):

1. Choose injection site: abdomen (preferred), thigh, or upper arm
2. Rotate sites daily to prevent local irritation or erythema

3. Cleanse area with alcohol wipe; allow 30 seconds to air dry
4. Pinch skin to create fold; insert needle at 45–90-degree angle
5. Inject slowly over 5–10 seconds
6. Withdraw needle and apply gentle pressure with sterile gauze
7. Do not massage injection site immediately post-injection

Intravenous Administration (requires clinical supervision):

1. Use sterile IV catheter or butterfly needle in antecubital vein
2. Flush with 0.5–1 mL sterile saline before administration
3. Inject cortistatin solution slowly over 2–3 minutes
4. Monitor for transient hypotension immediately post-injection
5. Remain recumbent for 5 minutes post-injection
6. Flush with saline again post-administration

Cycle Example: 10-Week Anti-Inflammatory Protocol

Subject: 180-pound (82 kg) individual

Post-Cycle: 3-week complete rest with no cortistatin administration

What to Expect: Timeline of Effects

Days 1–3: Minimal systemic effects; local injection site may show mild warmth or erythema (normal, resolves within 24 hours)

Days 4–7: Onset of anti-inflammatory signaling; possible mild fatigue or transient hypotension, particularly with IV administration; some individuals report improved sleep quality

Weeks 2–3: Measurable reduction in pro-inflammatory markers; improved joint mobility or reduction in pain; enhanced cognitive clarity during sleep phases

Weeks 4–6: Peak immunomodulatory effects; sustained reduction in inflammatory cytokines; noticeable improvement in recovery from physical stress or immune challenges

Weeks 7–10: Plateau of anti-inflammatory benefits; sustained effects on slow-wave sleep and immune suppression of autoimmune responses; possible slow decrease in hunger or appetite signals (ghrelin receptor activation complexity)

Post-Cycle (Days 1–7): Gradual restoration of baseline inflammatory tone; possible rebound in sleep patterns within 3–5 days; immune markers normalize by week 2

Signs It's Working vs. When to Adjust

Indicators of Efficacy:

• Reduction in inflammatory markers (CRP, TNF-α, IL-6) via bloodwork
• Improved joint mobility and reduced pain scores
• Enhanced slow-wave sleep architecture on sleep tracking devices
• Faster recovery from immune challenges or infection exposure
• Improved GI symptoms or reduced bowel inflammation markers
• Reduced brain fog or improved cognitive sharpness during daytime

Signs to Reduce Dose:

• Excessive daytime sedation or somnolence (reduce by 10–15 mcg/kg)
• Persistent hypotension or orthostatic symptoms (reduce by 15–20 mcg/kg or switch to SC administration)
• Bradycardia below 50 bpm at rest (reduce dose immediately or pause cycle)
• Severe injection site irritation or persistent erythema (switch site rotation or reduce SC dose by 20%)
• Excessive growth hormone suppression symptoms (fatigue, poor wound healing—reduce SSTR2/5 activation via dose reduction)

Signs to Discontinue:

• Cardiac arrhythmias or severe hypotension
• Severe systemic hypersensitivity reaction
• Inability to maintain functional wakefulness despite dose reduction

Common Protocol Mistakes

1. Escalating too quickly: Jumping from 30 to 80 mcg/kg within 2 weeks causes excessive bradycardia and hypotension. Always follow 2-week minimum at each dose level.

2. Injecting same site repeatedly: Causes local erythema, fibrosis, and absorption inconsistency. Rotate abdomen → thigh → arm daily.

3. IV administration without clinical monitoring: Cortistatin causes transient hypotension post-IV injection. Always remain recumbent 5 minutes post-administration and have emergency support available.

4. Neglecting hydration and electrolytes: Bradycardia and sleep effects mask dehydration. Maintain 3–4 liters water daily and monitor sodium intake.

5. Cycling continuously without rest periods: Immune suppression compounds; SSTR activation reduces GH and insulin signaling. Minimum 2–4 week rest is non-negotiable.

6. Using single dose timing without adjustment: Evening dosing for sleep protocols ensures slow-wave enhancement; morning for GI protocols optimizes transit. Match timing to goal.

7. Ignoring injection site irritation early: Local erythema can progress to nodules if site rotation fails. Switch to different anatomical location immediately.

8. Stacking with other immune-suppressing compounds without monitoring: Cortistatin + immunosuppressive drugs or supplements risks over-suppression. Reduce stacked compound dosing by 25–50%.

How to Stack with Other Compounds

Compatible Stacking Protocols:

Anti-Inflammatory Stack (cortistatin + curcumin + omega-3):

• Cortistatin: 50 mcg/kg daily
• Curcumin: 1–2 grams daily (enhances anti-inflammatory effects synergistically)
• Omega-3 (EPA/DHA): 3–4 grams daily (supports immune modulation without duplication)
• Duration: 8–12 weeks, same cycle length
• Monitor: Reduce cortistatin dose by 15% if combined inflammatory suppression causes excessive fatigue

Sleep & Recovery Stack (cortistatin + magnesium glycinate + L-theanine):

• Cortistatin: 40–50 mcg/kg daily, evening dosing
• Magnesium glycinate: 300–400 mg, 30 minutes before cortistatin injection
• L-theanine: 100–200 mg, same timing as magnesium
• Duration: 6–8 weeks
• Synergy: Magnesium potentiates SSTR activation; L-theanine supports GABA signaling
• Monitor: Excessive sedation may occur; reduce L-theanine to 50 mg if needed

Joint Protection Stack (cortistatin + collagen peptides + glucosamine):

• Cortistatin: 60–70 mcg/kg daily
• Hydrolyzed collagen: 10–15 grams daily (type II and III)
• Glucosamine sulfate: 1,500 mg daily
• Duration: 10–12 weeks
• Synergy: Cortistatin suppresses cartilage-degrading inflammation while collagen provides substrate
• Monitor: No significant drug interactions; full stacking recommended

Avoid Stacking:

• Cortistatin + exogenous growth hormone: SSTR2/5 activation suppresses endogenous GH; exogenous GH creates paradoxical axis suppression
• Cortistatin + aggressive caloric restriction: Ghrelin receptor activation may dysregulate appetite signals during fasting protocols
• Cortistatin + high-dose beta-blockers: Additive bradycardia risk; requires medical monitoring

Protocol Quick Reference

Final Considerations

Monitoring Parameters During Cycling:

• Blood pressure and resting heart rate (daily, same time)
• Inflammatory markers: CRP, TNF-α, IL-6 (baseline, week 4, week 8, post-cycle)
• Growth hormone and insulin fasting levels (baseline and week 6 for longer cycles)
• Liver and kidney function (baseline and